Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RAPT Therapeutics (RAPT) EBITDA: 2018-2023

Historic EBITDA for Therapeutics (RAPT) over the last 6 years, with Dec 2023 value amounting to -$116.7 million.

  • Therapeutics' EBITDA fell 36.09% to -$30.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$116.7 million, marking a year-over-year decrease of 39.46%. This contributed to the annual value of -$116.7 million for FY2023, which is 39.46% down from last year.
  • According to the latest figures from FY2023, Therapeutics' EBITDA is -$116.7 million, which was down 39.46% from -$83.7 million recorded in FY2022.
  • Therapeutics' EBITDA's 5-year high stood at -$43.0 million during FY2019, with a 5-year trough of -$116.7 million in FY2023.
  • Its 3-year average for EBITDA is -$89.9 million, with a median of -$83.7 million in 2022.
  • Data for Therapeutics' EBITDA shows a maximum YoY plummeted of 39.46% (in 2023) over the last 5 years.
  • Over the past 5 years, Therapeutics' EBITDA (Yearly) stood at -$43.0 million in 2019, then fell by 23.54% to -$53.1 million in 2020, then tumbled by 30.41% to -$69.2 million in 2021, then dropped by 20.84% to -$83.7 million in 2022, then slumped by 39.46% to -$116.7 million in 2023.